Print Page  Close Window
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
11/08/17Paratek Pharmaceuticals Reports Third Quarter 2017 Financial Results, Remains on Track to Complete NDA Submissions in First Quarter of 2018 
11/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
10/24/17Paratek Pharmaceuticals to Report Third Quarter 2017 Financial Results and Provide Update on Clinical Progress on November 8, 2017 
10/06/17Phase 3 Optic Study Microbiology Data Demonstrate Omadacycline has Potent In vitro Activity Against Multiple Pneumonia Pathogens, Including Resistant Bacteria 
10/06/17Consistent Efficacy and Safety Profile Observed in New Analyses of OASIS-1 Phase 3 Study of Omadacycline in Patients with Difficult to Treat Comorbid Conditions 
10/02/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
09/25/17Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017 
09/21/17Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections 
09/19/17Paratek Pharmaceuticals, Inc. to Host Investor Day on October 17, 2017 
09/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
08/22/17Paratek Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences 
08/08/17Paratek Pharmaceuticals, Inc. to Present at Wedbush PacGrow Healthcare Conference 
08/02/17Paratek Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results and Provides Clinical Update 
08/01/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
07/19/17Paratek Pharmaceuticals to Report Second Quarter 2017 Financial Results and Provide Update on Clinical Progress on August 2, 2017 
07/17/17Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections 
07/07/17Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) 
06/14/17Paratek Pharmaceuticals, Inc. to Participate in JMP Securities Life Science Conference 
06/03/17New Microbiology Data Reinforce Activity of Paratek’s Omadacycline Against Pathogens of Importance in Respiratory, Skin and Urinary Tract Infections 
05/24/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ASM Microbe 2017 
05/08/17Paratek Announces Completion of Enrollment for Oral-only Omadacycline Phase 3 Skin Study, Top-line Data Expected in Mid-July 
05/04/17Paratek Pharmaceuticals, Inc. Reports First Quarter 2017 Financial Results and Provides Clinical Update 
04/26/17Paratek Pharmaceuticals to Report First Quarter 2017 Financial Results and Provide Update on Clinical Progress on May 4, 2017 
04/25/17Omadacycline Concentrations Exceed Tigecycline Levels in Lungs and Epithelial Lining Fluid According to Pharmacokinetic/Pharmacodynamic (PK/PD) Data 
04/24/17Paratek Pharmaceuticals and Zai Lab Announce Collaboration, Development and License Agreement for Omadacycline in China 
04/24/17New Health Economics Studies Highlight the Potential for Paratek Pharmaceuticals’ Omadacycline to Provide Cost-Savings Compared to Standard of Care for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections 
04/24/17New Microbiology Data from Paratek Pharmaceuticals Show Omadacycline Effective Against Most Common Skin Infections and Pathogens, Including MRSA 
04/18/17Paratek Pharmaceuticals to Present New Data from Omadacycline Development Program at ECCMID 2017 
04/03/17Paratek Announces Positive Phase 3 Study of Omadacycline in Community-Acquired Bacterial Pneumonia 
03/27/17Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne 
03/24/17Paratek Pharmaceuticals Opens New Office in King of Prussia 
03/02/17Paratek Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter 2016 Financial Results and Provides Clinical Update 
02/22/17Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017 
02/08/17Paratek Pharmaceuticals, Inc. to Present at LEERINK Partners 6th Annual Global Healthcare Conference 
01/18/17Paratek Announces Completion of Enrollment in Omadacycline Phase 3 Community-Acquired Bacterial Pneumonia Study 
01/04/17Paratek Pharmaceuticals Announces Promotion of Evan Loh, M.D. to the role of President and Chief Operating Officer